Rate Video

ASH 2014 | ASH 2014: Phase II SPRINT study of lenalidomide in relapsed/refractory mantle cell lymphoma

Marek Trněný • 5 Dec 2015

Mantle Cell Lymphoma Lenalidomide

Prof Marek Trněný (Charles University Hospital, Prague, Czech Republic) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses the phase 2 SPRINT (MCL-002) study of lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma, including the study design, efficacy and safety endpoints, and conclusions

Prognostic indices for follicular lymphoma: PRIMA-PI

Marek Trněný • 14 Jun 2018

SPRINT trial: Lenalidomide for relapsed/refractory mantle cell lymphoma

Marek Trněný • 12 Jun 2015

Message to mantle cell lymphoma physicians and patients

Marek Trněný • 23 Sep 2016

iwNHL 2017 highlights: the PDX model

Marek Trněný • 8 Sep 2017

Related Videos

Primary results from the Phase III SHINE study: ibrutinib + BR for older patients with MCL

Michael Wang • 11 Jun 2022

ZILO-301: Phase III study of zilovertamab + ibrutinib vs ibrutinib in R/R MCL

Salim Yazji • 10 Jun 2022

Zanubrutinib monotherapy in R/R indolent NHL

Tycel Phillips • 5 Jun 2022

Real-world treatment patterns and comparative effectiveness of BTKi in patients with MCL

Bijal Shah • 4 Jun 2022